N. prodotti: 0
Totale ordine: € 0,00
A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413
Online ISSN 1827-1936
Weiss K. 1, Palumbo B. 2, Palumbo I. 2, Palumbo R. 2, Granegger S. 3, Hiltunen J. 4, Sinzinger H. 3
1 Department of Nuclear Medicine Hospital Wr. Neustadt, Austria
2 Institute of Nuclear Medicine University of Perugia, Perugia, Italy
3 Department of Nuclear Medicine University of Vienna, Vienna, Austria
4 Laboratory of Radiochemistry, Department of Chemistry University of Helsinki, Helsinki, Finland
Aim. Aim of the study was to assess whetheré [153Sm] EDTMP therapy at a low-dose is associated with platelet activation.
Methods. In 29 patients suffering from metastatic prostate cancer platelet count and various platelet function parameters have been monitored for 2 months after a single (the first) application of 1.1 GBq mCi [153Sm]EDTMP.
Results. After 3 days insignificant signs of platelet activation (increase in malondialdehyde, adenosine diphosphate-induced platelet aggregation, decreased platelet sensitivity) occur, normalizing rapidly. At the nadir of platelet count (3-4 weeks) platelet aggregation response in non-count adjusted samples is somewhat lower, while activity per cell (count adjusted samples) is unchanged. Platelet proteins do not change at all. Insignificant activation of platelet function at day 3 is interpreted as an indicator of mild oxidation injury, late aggregation response changes in non-adjusted samples seem only to reflect temporarily decreased number of circulating platelets. Samarium-153-EDTMP therapy at doses (1.1 GBq) used in the Vienna-protocol is not associated with a significantly altered functional behavior of platelets.
Conclusion. We conclude that a single dose of 1.1 GBq 153Sm-EDTMP does not significantly affect in vivo and ex vivo platelet function.